BillionToOne stock

BillionToOne Stock

HealthTech

Looking to sell BillionToOne stock or options?

Founded: 2016Funding to Date: $408Mhttps://www.billiontoone.com

BillionToOne is a molecular diagnostics company that aims to create prenatal and oncology assays with unparalleled sensitivity and precision. It provides an ultra-sensitive comprehensive genomic profiling assay that identifies more actionable mutations for selecting treatments. BillionToOne also offers a pan-cancer tumor-naive oncology test, which accurately measures tumor burden from a blood sample to monitor therapy response. Their prenatal tests offer more than simple aneuploidy detection, identifying single-gene disorders like sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a straightforward blood test.

Investors Include:

Shahram Seyedin-Noor, Keyan Li, Adams Street Partners, Pacific 8 Ventures, Metaplanet Holdings, Endpoint Ventures, Lombardstreet Ventures, NewDo Venture, Hummingbird Ventures, Baillie Gifford, Start Capital, U.S. Department of Health and Human Services, Enis Hulli, Norwest Venture Partners, Sandy Kory, e2vc, 500 Global, Civilization Ventures, Wei Guo, MengKe Li, Rina Onur, Luigi Bajetti, Neuberger Berman, Eczacıbaşı Momentum, Lawrence Diao.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more